GlaxoSmithKline sues Lupin over Combivir patent
This article was originally published in Scrip
GlaxoSmithKlinehas filed a suit against Lupinin the US district court of Delaware claiming infringement of its patent for the anti-AIDS drug Combivir (lamivudine 150mg and zidovudine 300mg). The US FDA had in September 1997 granted approval to GSK to sell Combivir tablets. GSK claims that it will be irreparably harmed by Lupin's infringing activities unless enjoined by court. It has claimed monetary relief should Lupin manufacture and sell the product in the US or import the product before the expiry of the patent. Lupin's managing director, Dr Kamal Sharma, said that Lupin had filed a paragraph IV certification for GSK's patent for Combivir and is confident of the merit of its case. Lupin said that it is committed to bringing down healthcare costs worldwide through world-class quality generics and play a critical role in enhancing access to medicine for a larger patient population.
You may also be interested in...
New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…